Get the Stockscreener App
43.36
3.15%
-1.41
After Hours:
43.61
0.25
+0.58%
Bright Minds Biosciences Inc stock is traded at $43.36, with a volume of 74,411.
It is down -3.15% in the last 24 hours and up +22.30% over the past month.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$44.77
Open:
$45
24h Volume:
74,411
Relative Volume:
1.63
Market Cap:
$305.43M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-32.91
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+0.79%
1M Performance:
+22.30%
6M Performance:
+27.94%
1Y Performance:
+3,483%
1-Day Range:
$42.55
$45.00
1-Week Range:
$41.00
$45.00
52-Week Range:
$0.94
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
43.36 | 317.18M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Why Bright Minds Biosciences Inc. is moving todayJuly 2025 Trade Ideas & Verified Entry Point Detection - Newser
Will Bright Minds Biosciences Inc. benefit from macro trendsTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - Newser
Visual analytics tools that track Bright Minds Biosciences Inc. performanceStock Surge & Free High Accuracy Swing Entry Alerts - Newser
What momentum shifts mean for Bright Minds Biosciences Inc.2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
Is Bright Minds Biosciences Inc. stock bottoming outMarket Performance Report & Daily Entry Point Alerts - Newser
Analyzing Bright Minds Biosciences Inc. with risk reward ratio chartsJuly 2025 Weekly Recap & Daily Profit Focused Stock Screening - Newser
Applying Wyckoff theory to Bright Minds Biosciences Inc. stock2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
How to read the order book for Bright Minds Biosciences Inc.2025 Risk Factors & Expert Approved Momentum Ideas - Newser
RKTN(rocket token space) Price PredictionMarket Activity Report & Stepwise Entry and Exit Trade Signals - Newser
Forecasting Bright Minds Biosciences Inc. price range with options dataNew Guidance & Smart Money Movement Alerts - Newser
Volume spikes in Bright Minds Biosciences Inc. stock – what they meanJuly 2025 Movers & Safe Capital Investment Plans - Newser
Using economic indicators to assess Bright Minds Biosciences Inc. potentialJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - Newser
Earnings visualization tools for Bright Minds Biosciences Inc.Market Weekly Review & Daily Stock Trend Watchlist - Newser
Financial Comparison: Bright Minds Biosciences (NASDAQ:DRUG) & Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
CNS Drug Developer Bright Minds Biosciences Lines Up Four Major Healthcare Conference Presentations - Stock Titan
Sentiment analysis tools applied to Bright Minds Biosciences Inc.Weekly Trend Recap & Comprehensive Market Scan Insights - Newser
How to track smart money flows in Bright Minds Biosciences Inc.July 2025 Decliners & Smart Money Movement Alerts - Newser
Bright Minds Biosciences Inc.’s Beta Climbs After Market VolatilityGap Down & Safe Entry Trade Reports - beatles.ru
FY2025 EPS Estimates for DRUG Raised by Cantor Fitzgerald - Defense World
HC Wainwright Has Positive Outlook of DRUG FY2025 Earnings - Defense World
Should I set a stop loss on Bright Minds Biosciences Inc.July 2025 Update & Free Risk Controlled Daily Trade Plans - theviewers.co.kr
Smart tools for monitoring Bright Minds Biosciences Inc.’s price actionPortfolio Value Summary & Low Risk High Reward Trade Ideas - Newser
Is There Enough Volume to Lift Bright Minds Biosciences Inc.Market Activity Recap & Stepwise Trade Signal Implementation - mustnews.co.kr
Bright Minds Biosciences: Bright Prospects for Epilepsy Treatment with BMB-101 and Strong Financial Position - AInvest
HC Wainwright & Co. Reiterates "Buy" Rating for Bright Minds Biosciences with $85 Price Target - AInvest
Bright Minds Biosciences Reports Q3 2025 Financial Results - MSN
Bright Minds Biosciences stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
Bright Minds Biosciences stock maintains Buy rating at H.C. Wainwright - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Given Buy Rating at HC Wainwright - Defense World
New Product Launches: Will They Boost Bright Minds Biosciences Inc. Stock in 2025Market Rally & Advanced Technical Signal Analysis - Newser
What makes Bright Minds Biosciences Inc. stock price move sharplyStop Loss & Stepwise Swing Trade Plans - Newser
Using flow based indicators on Contineum Therapeutics Inc.Weekly Stock Recap & Weekly Stock Performance Updates - Newser
Bright Minds Biosciences Inc. stock outlook for YEAR2025 Bull vs Bear & AI Forecasted Stock Moves - Newser
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Price Target at $83.25 - Defense World
Bright Minds Biosciences Inc. Stock Recovery Path — Analyst BreakdownMarket Rally & Reliable Price Breakout Alerts - beatles.ru
Bright Minds rally ends as psychedelic stocks extend volatility - MSN
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):